Skip to main content
Terug
Watch Compare

Silexion Therapeutics Corp

Datakwaliteit: 83%
Ook genoteerd als SLXNW NASDAQ
SLXN
NASDAQ Manufacturing Chemicals
€ 1,00
▼ € 0,02 (-1,96%)
6 months return
—
Momentum
Neutral
ROE
-335,69%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-335,69%
Onder sectorgemiddelde (-54,47%)
ROIC-147,32%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,97
Interest CoverageN/A

Waardering

PE (TTM)
-0,31
Boven sectorgemiddelde (-1,50)
P/B Ratio0,53
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -10,83 M

Price History

Financiële Trends

Koersdoel Analisten

2 analisten
Strong Buy
+500.0%
upside to target
Huidig
€ 1,00
Consensus Target
€ 6,00
€ 6,00
Laag
€ 6,00
Hoog
Vooruitzicht
Forward WPA
-€ 2,87
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 1,29 · Rev Est: 0,0
Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 2,88 — — —
Estimate -€ 3,40 -€ 1,12 -€ 1,29 -€ 1,31
Verrassing +15,29% — — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -335,69% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -11,91 M
ROE -335,69% ROA -136,83%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10,83 M
ROIC -147,32% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,97
Debt / Equity N/A Current Ratio 3,97
Interest Coverage N/A Asset Turnover N/A
Working Capital 8,27 M Tangible Book Value 6,98 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,31 · EV/EBITDA: N/A
P/E Ratio -0,31 Forward P/E N/A
P/B Ratio 0,53 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -292,87%
Market Cap 3,70 M Enterprise Value -5,55 M

Per Share

EPS: 8,96 · FCF/Share: -3,25
EPS (Diluted TTM) 8,96 Revenue / Share N/A
FCF / Share -3,25 OCF / Share -3,25
EPS CAGR (1Y) -66,01% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 90,90% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 90,90%
SBC-Adj. FCF -10,99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -11,91 M -16,52 M
EPS (Diluted) 8,96 26,36
Gross Profit — —
Operating Income -11,63 M -12,57 M
EBITDA — —
R&D Expenses 7,14 M 5,82 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 3.000,0 10.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 7,22 M 2,86 M
Total Liabilities 4,61 M 6,85 M
Shareholders' Equity 2,60 M -3,99 M
Total Debt — —
Cash & Equivalents 5,99 M 1,19 M
Current Assets 6,64 M 2,25 M
Current Liabilities 2,76 M 3,52 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 0,5 1,6
ROE % -335,7 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3